TTPH
Tetraphase Pharmaceuticals, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
Market Cap: 16 Million
Primary Exchange: NASDAQ
Website: http://www.tphase.com
Shares Outstanding: 7.26 Million
Float: 5.42 Million
Dividend: (%)
Beta: 1.2203287606185333
Sector: Health Technology
Industry: Pharmaceuticals: Other
Ethical Flags
Longest drawdown: 1270 trading days
From: 2015-07-16 To: 2020-07-28
Lowest Point:
Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting
via: Business Wire at 2019-06-13 03:00:00:000
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that new data will be presented at the American Society for Microbiology (ASM) Microbe… read more...
Tetraphase down 4% after hours on downsizing plan
via: SeekingAlpha at 2019-06-12 12:45:38:000
Aimed at maximizing the commercial opportunity for XERAVA (eravacycline), Tetraphase Pharmaceuticals (NASDAQ: TTPH ) will eliminate its internal research function, a move expected to save about $8M a year. More news on: Tetraphase Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th… read more...
Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA(TM) (Eravacycline) Commercial Opportunity
via: Business Wire at 2019-06-12 12:01:00:000
Company to Eliminate Internal Research Function and Explore Pipeline Out-licensing Opportunities to Focus the Companys Resources on XERAVA Commercial Success Workforce and R&D Expense Reduction Expected to Result in Annualized Savings of Approximately $8 Million … read more...
Tetraphase up 11% on retrospective Xerava data
via: SeekingAlpha at 2019-06-10 10:09:41:000
Nano cap Tetraphase Pharmaceuticals ( TTPH +11% ) is up on below-average volume in response to results from three studies that support the value proposition of antibiotic XERAVA (eravacycline), approved in the U.S. in April 2018 for the treatment of complicated intra-abdominal infections… read more...
Tetraphase up 11% on retrospective Xerava data
via: SeekingAlpha at 2019-06-10 10:09:41:000
Nano cap Tetraphase Pharmaceuticals ( TTPH +11% ) is up on below-average volume in response to results from three studies that support the value proposition of antibiotic XERAVA (eravacycline), approved in the U.S. in April 2018 for the treatment of complicated intra-abdominal infections… read more...
Tetraphase Pharmaceuticals Announces New XERAVA(TM) (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting
via: Business Wire at 2019-06-10 03:00:00:000
-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients- -Data Underscore XERAVAs Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections- Tetraphase Pharmaceuticals, Inc. (NASDA… read more...
Tetraphase Pharmaceuticals Announces New XERAVA(TM) (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting
via: Business Wire at 2019-06-10 03:00:00:000
-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients- -Data Underscore XERAVAs Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections- Tetraphase Pharmaceuticals, Inc. (NASDA… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|